Dehydroepiandrosterone Sulfate and Colorectal Cancer Risk: A Mendelian Randomization Analysis

Dulari K. Jayarathna1,2, Miguel E. Rentería2,3, Pik Fang Kho4, Jyotsna Batra1,3,5 and Neha S. Gandhi1,5

1Centre for Genomics and Personalised Health, School of Chemistry and Physics, Queensland University of Technology, Brisbane, Queensland, Australia, 2Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, 3School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia, 4Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA and 5Translational Research Institute, Brisbane, Queensland, Australia

Abstract
Colorectal cancer is the third most common and second most deadly type of cancer worldwide, with approximately 1.9 million cases and 0.9 million deaths worldwide in 2020. Previous studies have shown that estrogen and testosterone hormones are associated with colorectal cancer risk and mortality. However, the potential effect of their precursor, dehydroepiandrosterone sulfate (DHEAS), on colorectal cancer risk has not been investigated. Therefore, evaluating DHEAS’s effect on colorectal cancer will expand our understanding of the hormonal contribution to colorectal cancer risk. In this study, we conducted a two-sample Mendelian randomization (MR) analysis to investigate the causal effect of DHEAS on colorectal cancer. We obtained DHEAS and colorectal cancer genomewide association study (GWAS) summary statistics from the Leipzig Health Atlas and the GWAS catalog and conducted MR analyses using the TwoSampleMR R package. Our results suggest that higher DHEAS levels are causally associated with decreased colorectal cancer risk (odds ratio per unit increase in DHEAS levels 0.51, 95% confidence interval [0.51, 0.96]), which is in line with previous observations in a case–control study of colon cancer. The outcome of this study will be beneficial in developing plasma DHEAS-based biomarkers in colorectal cancer. Further studies should be conducted to interpret the DHEAS-colorectal cancer association among different ancestries and populations.

Keywords: Sex hormone precursors; dehydroepiandrosterone sulfate; colorectal cancer; two-sample Mendelian randomization

(Received 21 July 2022; accepted 21 July 2022; First Published online 2 September 2022)
In addition to studying the association between sex hormones and colorectal cancer risk, recent studies have focused on the effect of sex steroids and colorectal cancer precursors, including conventional adenomas and serrated polyps. Hang et al. (2021) investigated the association between plasma sex hormones and early initiation of colorectal cancer among 5404 postmenopausal women from the Nurses’ Health Study I and II. Using the multivariate logistic regression approach, they observed that higher concentrations of SHBG were associated with a lower risk of conventional adenomas. A nominally significant association between SHBG and a lower risk of large-serrated polyps (≥10 mm) was found. In addition to SHBG, free estradiol and free testosterone were associated with a higher risk of conventional adenomas. A recent study investigated the serum hormone levels (testosterone, androstenedione, DHEAS [dehydroepiandrosterone sulfate] and SHBG) and the risk of colorectal precursors among men (Figueiredo et al., 2022). Authors have found that levels of free testosterone, total testosterone, androstenedione, DHEAS or SHBG are not associated with either ‘low-risk’ (single tubular adenoma <1 cm) or ‘high-risk’ (advanced adenoma or sessile serrated adenoma or right-sided serrated polyps or >2 adenomas in any size) early precursor lesions in the colorectum.

Previous studies have investigated the causal effects of hormone-related traits such as age at menarche, age at menopause, using oral contraceptives and hormone replacement therapy (HRT) on colorectal cancer risk. Li et al. (2013) conducted a meta-analysis (11 case–control and 11 cohort studies) to assess the relationship between age at menarche and colorectal cancer. The random-effects pooled RR for the oldest versus the youngest age of menarche was 0.95 (95% CI [0.85, 1.06]) with significant heterogeneity (p < .001). Approximately similar RR values were obtained for separate case–control and cohort studies. Therefore, these RR results explained that age at menarche was not associated with colorectal cancer risk. Neumeyer et al. (2018) used an MR approach to test the causal effect of age at menarche and menopause on colorectal cancer risk. The authors found that age at menarche (OR = 0.98; 95% CI [0.95, 1.02]) and age at menopause (OR = 0.98; 95% CI [0.94, 1.01]) were not associated with colorectal cancer risk. Symer et al. (2018) conducted a meta-analysis among women aged 55 to 74 years to evaluate the colorectal cancer incidence (disease-specific mortality and all-cause mortality) on an individual’s use of HRT at the time of randomization: never, current or former users. The authors found that adjusted colorectal cancer incidence in current users compared to never-users was lower (HR = 0.81; 95% CI [0.69, 0.94]; p = .005), as was death from colorectal cancer (HR = 0.63; 95% CI = [0.47, 0.85]; p = .002) and all-cause mortality (HR = 0.76; 95% CI [0.72, 0.80]; p < .001).

Despite the accumulating evidence for the role of sex hormones in colorectal cancer, the effect of ‘sex hormone precursors’ has not been studied thoroughly. DHEAS is the precursor of major sex hormones in our body, testosterone in males and estrogen in females (see Figure 1). The concept for Figure 1 was adopted from Allolio and Arlt (2002).

DHEAS, the sulfated derivative of DHEA, is a steroid hormone produced mainly by the adrenal cortex, the outer layer of the adrenal glands. Osawa et al. (2002) have found that DHEA increases the number of aberrant crypt foci induced by azoxymethane in a murine model without progression to carcinogenesis, suggesting that DHEA may be a promising chemopreventive drug for colon cancer. DHEAS activates ERK1/2 in MCF-7 breast cancer cells (Upmanu et al., 2020). The ERK 1/2 cascade is a central signaling pathway that regulates various biological processes, including proliferation, differentiation, survival, apoptosis and stress response (Wortzel and Seger, 2011).

In 2000, Alberg et al. (2000) conducted a nested case–control analysis to evaluate whether serum DHEAS is associated with the likelihood of developing colon cancer. The results did not provide strong evidence for an association between circulating DHEAS and colon cancer risk. Nevertheless, DHEAS was associated with a decreased risk of colon cancer among men, and these results were not statistically significant under 95% CIs (p = .06). Therefore, further studies are required to support or refute the potential association between DHEAS and colorectal cancer.

MR is an epidemiological technique that leverages genetic data to provide evidence on causal relationships between pairs of complex traits. The variants must be robustly associated with the exposure as instrumental variables to predict the effect of the exposure (here DHEAS) on disease risk (colorectal cancer in this study). MR can be compared to a randomized controlled trial as it takes advantage of random allocation of genetic variants at conception (Larsson et al., 2022), while observational studies are susceptible to confounding. In this study, we have used a two-sample MR approach to assess the potential causal association of DHEAS with colorectal cancer. In two-sample MR, the associations of the instrumental variables with the exposure and outcome are derived from two independent (nonoverlapping) samples.

Materials and Methods

This study followed the STROBE-MR (strengthening the reporting of observational studies in epidemiology using MR) (Skrivankova et al., 2021) guidelines to report MR results.

Summary Data Resources

DHEAS. The genomewide association study (GWAS) summary statistics of DHEAS (adjusted for sex, age and log [BMI]) was obtained from Pott et al. (2019). In their study, GWAS analyses were performed using two cohorts of the Leipzig Research Centre for Civilization Diseases, Life-Adult (5758 samples: 2969 men and 2789 women) and Life-Heart (2070 samples: 1358 men and 712 women), after excluding all patients under treatment of sex hormones or glucocorticoids. Both Life-Adult and Life-Heart studies comprise randomly assigned participants from Leipzig, Germany. In Life-Heart and Life-Adult, the DHEAS levels were measured using liquid chromatography–tandem mass spectrometry and an electrochemiluminescence immunoassay. The unit of DHEAS measurement was μmol/L.

Colorectal cancer. The GWAS summary statistics of colorectal cancer were obtained from a recent study that included 4562 cases and 382,756 controls of white British ancestry (Zhou et al., 2018).

DHEAS and colorectal cancer GWAS summary statistics were obtained from two independent studies to avoid overlapping samples.

Instruments Selection

Summary statistics for 467 genetic variants (single nucleotide polymorphisms; SNPs) associated with DHEAS levels at genomewide significance (p < 5E-08 and MAF > 0.01) were extracted from the original DHEAS GWAS study (Pott et al., 2019). To ensure instrumental variables were independent, strict clumping was performed with an r² threshold of .001 and a window size of 10,000 kb using the
ld_clump function in the TwoSampleMR package (Hemani et al., 2018). Six instrumental variables (SNPs) were retrieved by the linkage disequilibrium pruning. We queried both PhenoScanner v2 (http://www.phenoscanner.medschl.cam.ac.uk/ accessed on February 8, 2022) and GWAS Catalog (https://www.ebi.ac.uk/gwas/home accessed on February 8, 2022) to investigate the potential confounding effect \( p < 5 \times 10^{-8} \) among instrumental variables and their proxies \( (r^2 > .8) \). Particularly, we checked obesity-related traits (BMI index, waist circumference, hip circumference and weight; Doleman et al., 2016), physical activity (Shaw et al., 2018), smoking (Botteri et al., 2020), alcohol consumption (Y. Kim et al., 2019), inflammatory bowel disease (Nørgaard et al., 2011) and Crohn’s disease (Olén et al., 2020), as reported in the literature. One SNP, rs117978821, was removed as it was associated with weight-related traits. These rigorously selected SNPs were used in the subsequent MR analyses.

**MR Analysis**

We used four complementary two-sample MR approaches, inverse-variance weighted (IVW), MR-Egger, weighted median and weighted mode, to estimate the causal effect of DHEAS on colorectal cancer. These methods have been derived under different assumptions of horizontal pleiotropy. The IVW method assumes no/balanced pleiotropy. The IVW estimate is calculated by meta-analyzing Wald ratio values of the individual instrumental variable. We used Cochran’s statistic \( (Q \sim \chi^2_L, \text{where } L \text{ is the number of instrumental variables}) \) to check the presence of heterogeneity, which can indicate pleiotropy under the null hypothesis of homogeneity.

MR-Egger regression is based on the INSIDE assumption (instrument strength independent of the direct effects). According to INSIDE, the instrumental variables’ pleiotropic effects should be independent instrumental variables’ association with the exposure. In addition to INSIDE, MR-Egger is also based on the no measurement error (NOME), where genetic associations with exposure of interest are measured without error. The regression dilution can evaluate the NOME assumption \( (I_{G \times X}^2) \). When \( 0.6 < I_{G \times X}^2 < 0.9 \), the simulation extrapolation (SIMEX) correlation analysis is used to estimate the causal effect. If \( I_{G \times X}^2 < 0.6 \), MR-Egger and SIMEX are unreliable, so neither is performed (Vermeulen et al., 2021). The intercept term of the Egger regression method is considered an estimate of the directional pleiotropic effect. The Rucker’s \( Q^* \) statistic \( (Q^* \sim \chi^2_L, \text{where } L \text{ is the number of instrumental variables}) \) was used to evaluate the heterogeneity in the MR-Egger method. In general, Rucker’s \( Q^* \) is less than or equal to Cochran’s \( Q \). If the difference of \( Q \) statistics, \( Q-Q^* \), is sufficiently large with respect to \( 3.84 \), we would infer that directional pleiotropy is an important factor and the MR-Egger model provides a better model than the IVW method.

Compared to IVW and MR-Egger, the weighted median method is more robust even when 50% of SNPs are invalid instruments. The weighted mode approach provides a consistent estimate when the largest number of similar instrumental variables come from valid instruments, even though the majority (>50%) are invalid. We used the MR pleiotropy residual sum and outlier (MR-PRESSO) global test to detect horizontal pleiotropy. Moreover, \( F \) statistics and the proportion of variance \( (R^2) \) were calculated to assess instrumental variables’ strength (Rees et al., 2017). Staiger and Stock (1997) suggested that the \( F \) statistic of instrumental variables should be larger than 10 to ensure that the maximum bias in instrumental variable estimators is less than 10%. The TwoSampleMR R package (Hemani et al., 2018) was utilized for all analyses explained in the Methods section except \( I_{G \times X}^2 \) calculation, which was performed using the MendelianRandomization R package (Yavorska and Burgess, 2017).

**Sensitivity Analysis**

Leave-one-out sensitivity analyses were carried out with significant MR analysis results to check whether the causal association is driven by a single SNP.

**Results**

**Two Sample MR Analysis Results**

The proportion of variance \( (R^2) \), \( F \) statistics and Wald estimates were calculated for each instrumental variable (Table 1). The...
Table 2. F statistic values and Wald ratio estimates for individual instrumental variables

| Instrumental variable | F statistic | Beta_{DHEAS-CRC} | SE_{DHEAS-CRC} | p_{DHEAS-CRC} |
|-----------------------|-------------|------------------|----------------|---------------|
| rs28620926            | 96.3        | −0.45            | 0.32           | 0.15          |
| rs29001546            | 78.9        | −0.38            | 0.29           | 0.19          |
| rs296360              | 75.4        | −0.29            | 0.31           | 0.34          |
| rs57159061            | 47.7        | −0.95            | 0.35           | 0.01          |
| rs615567              | 97.6        | 0.07             | 0.28           | 0.77          |

Note: SE, standard error; CRC, colorectal cancer; DHEAS, dehydroepiandrosterone sulfate

Table 2. MR causal estimate of DHEAS on colorectal cancer

| Method                  | Number of SNPs | Odds ratio | Confidence interval | p value |
|-------------------------|----------------|------------|---------------------|---------|
| Inverse-variance weighted (IVW) | 5              | 0.70       | (0.51, 0.96)        | 0.03    |
| Weighted median         | 5              | 0.70       | (0.49, 1.00)        | 0.05    |
| Weighted mode           | 5              | 0.69       | (0.41, 1.15)        | 0.22    |

Note: DHEAS, dehydroepiandrosterone sulfate; SNP, single nucleotide polymorphism.

combined multi-allelic instrument has explained 2.97% of the variation in DHEAS levels.

As shown in Table 1, the F statistic is greater than 10 for all the instrumental variables. IVW estimate exhibits an inverse association between DHEAS level and colorectal cancer risk (OR = 0.70; 95% CI [0.51, 0.96]; p = .03). According to Cochran’s Q statistic (Q = 5.47; p = .24), homogeneity was observed among individual IVW causal estimates. We did not fit MR-Egger models as I^2_{IVW} was close to zero. The Q’ (3.45; p = .33) and Q-Q’ (2.02; p value = .16) test statistics and respective p values indicated that the IVW method provides a better estimate. MR-PRESSO global test showed no horizontal pleiotropy among individual SNPs of DHEAS for colorectal cancer (p = .31), strengthening the selection of the IVW method to estimate the causal effect of DHEAS on colorectal cancer. Moreover, causal effects found from weighted median (OR = 0.70; 95% CI [0.49, 1.00]; p = .05) and weighted mode (OR = 0.69; 95% CI [0.41, 1.15]; p = .23) were consistent with IVW causal estimate (see Table 2).

Results in Table 2 (OR = 0.70; 95% CI [0.51, 0.96]; p = .03) and Figure 2 (IVW regression line in light blue color) imply an inverse relationship between DHEAS level and colorectal cancer risk.

Sensitivity Analyses (Leave-One-Out Analysis)

We used the leave-one-out analysis to check whether the SNPs are inconsistent in their effect on the overall outcome or whether a single outlying SNP is driving the results. Figure 3 illustrates the results of MR analyses using the IVW method when leaving one SNP out each time. Figure 3 shows a consistent effect size at the exclusion of most SNPs (three out of five, rs28620926, rs29001546 and rs296360).

Discussion

Colorectal cancer is one of the most common cancers in Western society, with a poor prognosis for patients in the advanced stages. Emerging evidence shows that sex hormones such as estrogen and testosterone may play an important role in colorectal cancer risk.

Nevertheless, the role of DHEAS, the precursor of estrogen and testosterone, was unclear. We conducted the first MR study that assesses the causal effect of endogenous DHEAS levels on colorectal cancer risk.

The MR analysis was conducted under three main assumptions. These assumptions should be satisfied to select genetic variants as instrumental variables: (1) the selected instrumental variables are robustly associated with the exposure; (2) the instrumental variables are not associated with confounding factors; and (3) the instrumental variables influence the outcome only through the exposure (no horizontal pleiotropy exists). Initially, we selected genetic variants at the genomewide significance level (5E-08) to reflect a strong association with the exposure, DHEAS. Furthermore, we calculated the F statistic for the selected SNPs. All instrumental variables have F statistic >10, satisfying the first assumption. We have minimized the violation of the second assumption by examining previously reported associations of instrumental variables. One genetic variant, rs117978821, was removed as it was associated with weight-related traits (BMI is considered a potential risk factor in colorectal cancer). These findings may be limited as there can be undiscovered risk factors of colorectal cancer. Herein, we did not perform MR-Egger (intercept analysis) as I^2_{IVW} was too low. Nevertheless, weighted median, Cochran’s Q, the difference of Q (Q-Q’) and MR-PRESSO test statistics detected the no/balanced horizontal pleiotropy satisfying the third assumption. Therefore, the IVW method was selected to estimate the causal effect.

In the present study, IVW estimates exhibit a significant association between DHEAS levels and decreased colorectal cancer risk. Lin et al. (2013) reported that testosterone levels and the ratio of estradiol to testosterone were associated with decreased colorectal cancer risk among men and women, respectively. Their results suggest that men with lower androgenicity due to reduced androgen receptor activity or lower circulating DHEAS are at higher risk of colorectal cancer. Yang et al. (2020) have found that higher circulating testosterone levels are associated with lower colorectal cancer risk among men, but higher estrone levels show increased colorectal risk among women. Previous studies have suggested an inverse relationship between testosterone and colorectal cancer risk among men, but the association between estrogen and colorectal cancer was not consistent among women. Our study was conducted using DHEAS GWAS summary statistics adjusted for the sex variable, and an inverse association was found between DHEAS and colorectal cancer. Moreover, Alberg et al. (2000) have mentioned that DHEAS was associated with a decreased risk of colon cancer among men, and these results were within the bounds of chance. Our outcome strengthens Alberg et al.’s (2000) results through the negative causal effect of DHEAS on colorectal cancer.

In addition to colorectal cancer, DHEAS (desulfated version of DHEAS)/DHEAS shows an association with other hormonal cancers such as prostate (Kim et al., 2016), breast (Hankinson and Eliassen, 2010; Tworoger et al., 2006), ovarian (Mizushima and Miyamoto, 2019) and endometrial (Michels et al., 2019) cancers. Kim et al. (2016) have explained DHEA as a potential biomarker in metastatic castration-resistant prostate cancer. Nevertheless, case–control, cohort or MR studies were not found that investigated the DHEAS-prostate cancer association. Tworoger et al. (2006) described that DHEAS was associated with increased estrogen receptor/progesterone receptor-positive breast cancer risk in predominantly postmenopausal women. Later on, Hankinson and Eliassen (2010) explained that DHEA/S was associated with breast cancer risk...
among postmenopausal women and no significant association among premenopausal women. Similarly, Michels et al. (2019) have found that compared to the lowest level, the highest DHEA level (5th vs. 1st quintile: OR = 1.85; 95% CI [1.06, 3.25]) was associated with increased endometrial cancer risk among postmenopausal women. In early studies, Cuzick et al. (1983; \( p = .007 \)) and Helzlsouer et al. (1995; \( p = .02 \)) showed that DHEA levels were significantly higher in ovarian cancer patients than in control subjects. In contrast, later studies did not find a significant difference in blood levels of DHEA or DHEAS between ovarian cancer patients and matched controls (Lukanova et al., 2003; Ose et al., 2015; Rinaldi et al., 2007; Tworoger et al., 2008). These studies imply that DHEA/DHEAS plays an important role in multiple hormonal cancers.

There are several limitations of the current study that should be acknowledged. The present study used GWAS summary statistics from the cohorts that dominated European ancestry; hence, results may not be generalized to other populations. Moreover, MR captures lifelong exposure to DHEAS; the MR effect may not be similar to the short-term effect of randomized clinical trials. Therefore, the effect of DHEA/DHEAS on colorectal cancer still needs to be studied in intervention studies. Herein, we conducted MR analysis for sex-adjusted DHEAS GWAS summary statistics as a sufficient number of SNPs were not retained by men- or women-specific DHEAS GWAS. Though DHEAS GWAS summary data are adjusted for sex groups, the potential residual effect of this covariate cannot be excluded, which may violate the first assumption that instrumental variables are robustly related to the exposure.

Fig. 2. A scatter plot representation relating the effect sizes of SNP (single nucleotide polymorphism)-DHEAS (dehydroepiandrosterone sulfate) association (x-axis, in standard deviation units) and SNP-colorectal cancer (y-axis) with standard error bars. The gradients of the lines correspond to causal estimates using each of the three different methods.

Fig. 3. Leave-one-out analysis using inverse-variance weighted (IVW) method. Each black point represents the IVW causal effect estimation of dehydroepiandrosterone sulfate (DHEAS) on colorectal cancer, excluding that particular variant (labeled on the y-axis) from the analysis. The black point with a red error bar depicts the IVW estimate using all single nucleotide polymorphisms (SNPs). Each point of the plot has been labeled with effect sizes and their respective \( p \) values (within brackets).
Moreover, owing to the lack of data, the original DHEAS GWAS study has not been controlled for the menstrual cycle and using birth control methods. In leave-one-out sensitivity analyses, the exclusion of only one SNP was statistically significant under the 5% significance level (all five were significant at the 10% threshold), showing that results are influenced by the small number of SNPs used in the analysis. A lower number of SNPs can also affect the utility of other MR methods as testing heterogeneity is robust with higher SNPs.

Besides these limitations, this study provides a new direction for hormone-colorectal cancer risk association studies. DHEAS acts as the precursor of estrogen and testosterone. Unless DHEAS has a more significant effect than estrogen/testosterone on colorectal cancer or DHEAS is a more straightforward supplementation than estrogen or testosterone, DHEAS/estrogen/testosterone will still be valuable interventions.

Conclusions

Using publicly available GWAS summary statistics, we conducted two-sample MR analyses to investigate the causal effect of DHEAS on colorectal cancer. We identified an inverse relationship between DHEAS (adjusted for sex variable) and colorectal cancer risk. Nevertheless, MR explains lifelong exposure to DHEAS, which may not be analogous to the short-term effect of randomized clinical trials. Moreover, this study is based on data retrieved from the European ancestry-based databases and may not be extrapolated to other ancestries or populations. Apart from these limitations, this study provides a direction for future hormone-cancer risk association studies. Future MR analyses should focus on gender-based DHEAS-colorectal cancer association among different ancestries/populations.

Data Availability Statement. Publicly available DHEAS GWAS summary statistics were obtained from the Leipzig Health Atlas (https://tenodo.org/record/5702746#.YxYGt6oxmmE). The colorectal cancer GWAS summary statistics were downloaded from the GWAS Catalog (https://www.ebi.ac.uk/gwas/). PhenoScanner v2 (http://www.phenoscanner.medschl.cam.ac.uk/) and GWAS Catalog (https://www.ebi.ac.uk/gwas/home/) were used to identify previously reported traits/diseases for instrumental variables in this study. All statistical analyses and graph preparations were performed using the TwoSampleMR R package, and installation instructions and links are freely available at https://github.com/MRCIEU/TwoSampleMR.

Acknowledgments. The computational resources and services used in this work were provided by the eResearch Office, Queensland University of Technology, Brisbane, Australia.

Author Contributions. Conceptualization: D.K.J, N.S.G., M.E.R., and P.F.K.; methodology: D.K.J and P.F.K.; formal analysis: D.K.J.; writing—review and editing: D.K.J., N.S.G., M.E.R., P.F.K., and J.B.; supervision: N.S.G., M.E.R., and J.B. All authors read and approved the final manuscript.

Financial Support. This research was supported by QUT postgraduate research allowance (QUTPRA), QUT HDR tuition fee sponsorship, Advance Queensland Industry Research Fellowship; the NHMRC Career Development Fellowship; and the Cancer Council Queensland grant.

Conflict of Interest. None.

Ethical standards. This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committees of Queensland University of Technology (December 19, 2019/1900001147) and QIMR Berghofer Medical Research Institute (August 23, 2019/P1051).

References

Alberg, A. J., Gordon, G. B., Hoffman, S. C., Comstock, G. W., & Helzlsouer, K. J. (2000). Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and the subsequent risk of developing colon cancer. *Cancer Epidemiology, Biomarkers & Prevention*, 9, 517–521.

Allelo, B., & Arlt, W. (2002). DHEA treatment: Myth or reality? *Trends in Endocrinology and Metabolism*, 13, 288–294.

Aran, V., Victorino, A. P., Thuler, L. C., & Ferreira, C. G. (2016). Colorectal cancer: Epidemiology, disease mechanisms and interventions to reduce onset and mortality. *Clinical Colorectal Cancer*, 15, 195–203.

Botteri, E., Borroni, E., Sloan, E. K., Bagnardi, V., Bosetti, C., Peveri, G., Santucci, C., Specchia, C., van den Brandt, P., Gallus, S., & Lugo, A. (2020). Smoking and colorectal cancer risk, overall and by molecular subtypes: A meta-analysis. *American Journal of Gastroenterology*, 115, 1940–1949.

Cuzick, J., Bulstrode, J. C., Stratton, I., Thomas, B. S., Bulbrook, R. D., & Hayward, J. L. (1983). A prospective study of urinary androgen levels and ovarian cancer. *International Journal of Cancer*, 32, 723–726.

Dimou, N., Mori, N., Smith-Byrne, K., Papadimitriou, N., Bishop, D. T., Casey, G., Colorado-Yobar, S. M., Cotterchio, M., Cross, A. J., Marchland, L. L., Lin, Y., Offit, K., Orlado-Moret, N. C., Peters, U., Potter, J. D., Rohan, T. E. A., & Murphy, N. (2021). Circulating levels of testosterone, sex hormone binding globulin and colorectal cancer risk: Observational and Mendelian randomization analyses. *Cancer Epidemiology, Biomarkers & Prevention*, 30, 1336–1348.

Doleman, B., Mills, K. T., Lim, S., Zelhart, M. D., & Gagliardi, G. (2016). Body mass index and colorectal cancer prognosis: A systematic review and meta-analysis. *Techniques in Coloproctology*, 20, 517–535.

Figueiredo, J. C., Gresham, G., Barry, E. L., Mott, L. A., Passarelli, M. N., Bradshaw, P. T., Anderson, C. W., & Baron, J. A. (2022). Circulating sex hormones and risk of colorectal adenomas and serrated lesions in men. *Cancer Epidemiology, Biomarkers & Prevention*, 31, 293–295.

Hang, D., He, X., Kvarner, A. S., Chan, A. T., Wu, K., Ogino, S., Hu, Z., Shen, H., Giovannucci, E. L., & Song, M. (2021). Plasma sex hormones and risk of conventional and serrated precursors of colorectal cancer in postmenopausal women. *BMC Medicine*, 19, 18.

Hankinson, S. E., & Eliassen, A. H. (2010). Circulating sex steroids and breast cancer risk in premenopausal women. *Hormones & Cancer, 1*, 2–10.

Helzlsouer, K. J., Alberg, A. J., Gordon, G. B., Longcope, C., Bush, T. L., Hoffman, S. C., & Comstock, G. W. (1995). Serum gonadotropins and steroid hormones and the development of ovarian cancer. *JAMA*, 274, 1926–1930.

Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin, C., Burgess, S., Bowden, J., Langdon, R., Tan, V. Y., Yarmolinsky, J., Shihab, H. A., Timpson, N. J., Evans, D. M., Relton, C., Martin, R. M., Davey Smith, G., Gaunt, T. R., & Haycock, P. C. (2018). The MR-Base platform supports systematic causal inference across the human phenotype. *Elife*, 7, e34408.

Kim, W., Ryan, C. J., Zhang, L., Youngren, J., Wilton, J., Alumkal, J. J., Beer, T. M., Baertsch, R., Stuart, J., Chi, K. N., Gleave, M., Retting, R., Reiter, R. E., Lara, P., Evans, C. P., & Small, E. J. (2016). Dehydroepiandrosterone (DHEA) in metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Dream Team (WCDT). *Journal of Clinical Oncology*, 34, e16598–e16598.

Kim, Y., Je, Y., & Giovannucci, E. L. (2019). Association between alcohol consumption and survival in colorectal cancer: A meta-analysis. *Cancer Epidemiology, Biomarkers & Prevention*, 28, 1891–1901.

Larsson, S. C., Kar, S., Perry, J. R. B., Carter, P., Vithayathil, M., Mason, A. M., Easton, D. F., & Burgess, S. (2022). Serum estradiol and 20 site-specific cancers in women: Mendelian randomization study. *Journal of Clinical Endocrinology & Metabolism*, 107, e67–e47.

Li, C. Y., Song, B., Wang, Y. Y., Meng, H., Guo, S. B., Liu, L. N., Lv, H. C., & Wu, Q. J. (2013). Age at menarche and risk of colorectal cancer: A meta-analysis. *PloS One*, 8, e56465.

Lin, J. H., Zhang, S. M., Rexrode, K. M., Manson, J. E., Chan, A. T., Wu, K., Tworoger, S. S., Hankinson, S. E., Fuchs, C., Gaziano, J. M., Buring, J. E.,
